Skip to content

A prospective, double-blind, randomized controlled trial of remimazolam and cyclopropofol for the hemodynamic stability and quality of recovery after endoscopic retrograde cholangiopancreatography (ERCP)

A prospective, double-blind, randomized controlled trial of remimazolam and cyclopropofol for the hemodynamic stability and quality of recovery after endoscopic retrograde cholangiopancreatography (ERCP)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123984
Enrollment
Unknown
Registered
2026-05-06
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary and Pancreatic Diseases

Interventions

Remimazolam Group (Group R):Anesthesia Induction (Group R): Administer sufentanil 0.1–0.15 µg/kg intravenously, followed by remimazolam 0.25 mg/kg (>30 seconds), and then cisatracurium 0.15 mg/kg via
Ciprofol Group (Group C):Anesthesia Induction (Group C): Administer sufentanil 0.1–0.15 µg/kg intravenously, followed by ciprofol 0.4 mg/kg (>30 seconds), and then cisatracurium 0.15 mg/kg via slow in

Sponsors

The Affiliated Hospital of North China University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients who are scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia with endotracheal intubation. 2.Age 18 to 80 years, inclusive. 3.American Society of Anesthesiologists (ASA) Physical Status Class I-III. 4.Patient (or legally authorized representative) is willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: (1) allergy to study drugs; (2) foreseeable history of difficult airway and severe respiratory diseases (acute respiratory infection, acute exacerbation of COPD, uncontrolled asthma, etc.); (3) severe heart, liver and kidney dysfunction; (4) pregnant or lactating women; (5) hearing/vision/language disorders affecting communication; (6) long-term use of analgesics or psychotropic drugs for chronic pain; (7) not fit according to the investigator's judgment (inability to cooperate with mental illness, history of alcohol or drug abuse, etc.). (8) patients with postoperative tube in ICU

Design outcomes

Primary

MeasureTime frame
Blood Pressure;Heart Rate;Oxygen Saturation;Area Under the Curve of Hypotension (Hypotension AUC);

Secondary

MeasureTime frame
Quality of Recovery-15 (QoR-15);Time to Emergence;Incidence of Adverse Events;

Countries

China

Contacts

Public ContactLiu Tiejun

The Affiliated Hospital of North China University of Science and Technology

534169248@qq.com+86 177 3156 0119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026